Research Radartracking 2 published studies · 1 clinical trials · 2 cancer pages · updated Jun 2026Open the Research Map →

Phosphatidylcholine

Phospholipid: Membrane ↑, bile flow ↑, hepatotox ↓; moderate support in pancreatic/colorectal/HCC/breast chemo tolerance.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Moderate — Convergent preclinical and small clinical data for hepatoprotection; larger oncology trials needed.PCLecithinPolyenylphosphatidylcholine (PPC)

Forms: Liposomal capsules (500-1000 mg PC) · IV infusion (essential phospholipid for severe cases)

Educational only, not medical advice. OncoForge makes no claim that Phosphatidylcholine treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Replenishes cell and mitochondrial membranes, improves bile composition/flow, and helps protect the liver from chemo-related steatohepatitis and transaminitis. Human data suggest hepatoprotective and anti-inflammatory effects that can support treatment tolerance.

Evidence at a glance

Tier 2 · animalPancreaticColorectalHCCBreast

Preclinical membrane/bile dominance; phase II hepatoprotection signals in chemo cohorts; meta ALT SMD -0.3; ongoing in HCC/pancreatic; quality varies by source (soy/sunflower).

How it may work

As a major phospholipid, phosphatidylcholine (PC) restores membrane bilayers, stabilizes lipid rafts, and improves mitochondrial function under oxidative stress. In the liver, PC enriches biliary phospholipids, buffering bile-acid cytotoxicity, enhancing bile flow, and reducing cholestatic injury. PC modulates choline metabolism (SAMe/PC cycle), downshifts hepatic inflammation and stellate-cell activation, and can limit fibrosis progression.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

  • Membrane↑Bilayer restoration and lipid raft stabilization
  • Bile Flow↑Phospholipid enrichment in bile
  • Hepatotoxicity↓Buffering against oxidative/cholestatic injury
  • Mitochondrial Function↑Δψm preservation under stress
  • Inflammation↓Hepatic stellate-cell quiescence
MembraneBile FlowHepatotoxicity

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Overlapping mechanisms

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories
Gi UpsetTmao RiskAllergy Risk
Potential interactions
  • statinsMonitorLowTheoreticalCholine metabolism overlap; LFTs.
  • hepatotoxic_chemoSynergizeLowTheoreticalMitigates ALT/AST rises.
  • SorafenibSynergizeLowTheoreticalReduces HCC hepatotoxicity.

Timing

References

Research

No published studies for Phosphatidylcholine yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Phosphatidylcholine depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 500–2000 mg/day (po) divided BID; with meals for absorption, Hepatoprotection 1-2 g/day PPC; liposomal for bioavailability; monitor LFTs baseline and q4-6w..

Trials studying Phosphatidylcholine

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar